Franck J Barrat

Summary

Affiliation: Dynavax Technologies
Country: USA

Publications

  1. ncbi request reprint IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences
    Omar Duramad
    Dynavax Technologies, 717 Potter St, Ste 100, Berkeley, CA 94710, USA
    Blood 102:4487-92. 2003
  2. ncbi request reprint Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation
    Omar Duramad
    Dynavax Technologies, Berkeley, CA 94710, USA
    J Immunol 174:5193-200. 2005
  3. pmc Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 203:1999-2008. 2006
  4. pmc In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines
    Franck J Barrat
    DNAX Research Institute, Department of Immunology, Palo Alto, CA 94304, USA
    J Exp Med 195:603-16. 2002
  5. pmc Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 202:1131-9. 2005
  6. pmc TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
    Cristiana Guiducci
    Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA
    Nature 465:937-41. 2010
  7. pmc Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 207:2931-42. 2010
  8. ncbi request reprint Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Eur J Immunol 37:3582-6. 2007
  9. pmc RNA recognition by human TLR8 can lead to autoimmune inflammation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710
    J Exp Med 210:2903-19. 2013
  10. doi request reprint Development of TLR inhibitors for the treatment of autoimmune diseases
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunol Rev 223:271-83. 2008

Collaborators

Detail Information

Publications21

  1. ncbi request reprint IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences
    Omar Duramad
    Dynavax Technologies, 717 Potter St, Ste 100, Berkeley, CA 94710, USA
    Blood 102:4487-92. 2003
    ..The 3 distinct classes of ISS differed with respect to induction of PDC maturation and T-cell priming capacity. IL-10 regulated PDC activation but did not inhibit the subsequent T-cell-priming ability of PDCs already activated by ISS...
  2. ncbi request reprint Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation
    Omar Duramad
    Dynavax Technologies, Berkeley, CA 94710, USA
    J Immunol 174:5193-200. 2005
    ..IRS can also inhibit a complex pathological response to ISS, as shown by protection from death after massive systemic inflammation induced by a CpG-containing oligodeoxynucleotides...
  3. pmc Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 203:1999-2008. 2006
    ..This establishes that the primary determinant of TLR9 signaling is not valency but endosomal location and demonstrates a strict compartmentalization of the biological response to TLR9 activation in PDCs...
  4. pmc In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines
    Franck J Barrat
    DNAX Research Institute, Department of Immunology, Palo Alto, CA 94304, USA
    J Exp Med 195:603-16. 2002
    ..Generating homogeneous populations of IL-10-producing T cells in vitro will thus facilitate the use of regulatory T cells in immunotherapy...
  5. pmc Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 202:1131-9. 2005
    ..These inhibitors of TLR signaling thus represent novel therapeutic agents with potential for the treatment of lupus...
  6. pmc TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
    Cristiana Guiducci
    Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA
    Nature 465:937-41. 2010
    ..These findings unveil a new role for self nucleic acid recognition by TLRs and indicate that inhibitors of TLR7 and 9 signalling could prove to be effective corticosteroid-sparing drugs...
  7. pmc Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 207:2931-42. 2010
    ..These data suggest that inhibitors of TLR7 and TLR9 signaling have potential therapeutic application for the treatment of interface dermatitis...
  8. ncbi request reprint Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Eur J Immunol 37:3582-6. 2007
    ..These data demonstrate that in addition to its ability to block IFN-alpha, IRS 954 can reduce symptoms in a lupus model and thus represents a promising therapeutic agent for the treatment of SLE...
  9. pmc RNA recognition by human TLR8 can lead to autoimmune inflammation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710
    J Exp Med 210:2903-19. 2013
    ....
  10. doi request reprint Development of TLR inhibitors for the treatment of autoimmune diseases
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunol Rev 223:271-83. 2008
    ..We describe novel inhibitors of these receptors and provide evidence to support their use as novel therapeutic agents for autoimmunity...
  11. pmc PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 205:315-22. 2008
    ..Thus, PI3K selectively controls type I IFN production by regulating IRF-7 nuclear translocation in human pDCs and could serve as a novel target to inhibit pathogenic type I IFN in autoimmune diseases...
  12. pmc Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8
    Dipyaman Ganguly
    Department of Immunology, The University of Texas M D Anderson Cancer Center, TX 77030, USA
    J Exp Med 206:1983-94. 2009
    ..Our results demonstrate that the cationic antimicrobial peptide LL37 converts self-RNA into a trigger of TLR7 and TLR8 in human DCs, and provide new insights into the mechanism that drives the auto-inflammatory responses in psoriasis...
  13. ncbi request reprint Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
    Holger Kanzler
    Dynavax Technologies, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA
    Nat Med 13:552-9. 2007
    ..As recognition grows of the role of inappropriate Toll-like receptor stimulation in inflammation and autoimmunity, significant efforts have begun to develop antagonists to Toll-like receptors as well...
  14. ncbi request reprint Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses
    Kun Yang
    Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes INSERM U550, Necker Medical School, 75015 Paris, France
    Immunity 23:465-78. 2005
    ..The TLR-7-, TLR-8-, and TLR-9-dependent induction of IFN-alpha/beta and -lambda is strictly IRAK-4 dependent and paradoxically redundant for protective immunity to most viruses in humans...
  15. doi request reprint Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections
    Judith N Mandl
    Graduate Program in Population Biology, Ecology and Evolution, Emory University, 1510 Clifton Road, Atlanta, Georgia 30322, USA
    Nat Med 14:1077-87. 2008
    ..Such a vicious cycle of continuous virus replication and immunopathology is absent in natural sooty mangabey hosts...
  16. pmc Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients
    Emmanuel Xystrakis
    Medical Research Council and Asthma UK Centre in Allergic Mechanisms of Asthma at King s College London, Strand, London, United Kingdom
    J Clin Invest 116:146-55. 2006
    ..This strongly suggests that vitamin D3 could potentially increase the therapeutic response to glucocorticoids in SR patients...
  17. ncbi request reprint IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells
    Pedro L Vieira
    Division of Immunoregulation, The National Institute for Medical Research, London, United Kingdom
    J Immunol 172:5986-93. 2004
    ..These data show that Foxp3 expression is not a prerequisite for IL-10-T(Reg) activity in vitro or in vivo, and suggest that IL-10-T(Reg) and naturally occurring CD4(+)CD25(+) T(Reg) may have distinct origins...
  18. ncbi request reprint In vitro generation of IL-10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by Th1- and Th2-inducing cytokines
    Anne O'Garra
    Division of Immunoregulation, The National Institute for Medical Research NIMR, The Ridgeway, Mill Hill, NW7 1AA, London, UK
    Immunol Lett 85:135-9. 2003
  19. pmc Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis
    Michael F Denny
    Division of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Blood 110:2907-15. 2007
    ..SLE is characterized by an imbalance between endothelial cell damage and repair triggered by type I IFNs, which might promote accelerated atherosclerosis...
  20. pmc Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity
    Cheng Lung Ku
    Laboratory of Human Genetics of Infectious Diseases, U550, Institut National de la Sante et de la Recherche Medicale, 75015 Paris, France
    J Exp Med 204:2407-22. 2007
    ..Conversely, IRAK-4-dependent human TLRs appear to play a redundant role in protective immunity to most infections, at most limited to childhood immunity to some pyogenic bacteria...
  21. ncbi request reprint Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Lionel Apetoh
    Institut Gustave Roussy IGR, 39 rue Camille Desmoulins, F 94805 Villejuif, France
    Nat Med 13:1050-9. 2007
    ..These results delineate a clinically relevant immunoadjuvant pathway triggered by tumor cell death...